President & CBO, LumaCyte Precision PAT Analytics | Label-Free Cellular Fitness & Characterization | Real-Time Production Monitoring | Potency Assays
With the current downturn and significant layoffs across the biopharma sector, outsourcing has become a vital component in ensuring future success for these impacted organizations. The CDMO space is incredibly rich in both volume of opportunities but also competition. Now more than ever these companies must innovate to differentiate… derisking sponsor projects through novel analytics and methods that deliver consistent results with increased speed and quality. CDMOs have a very unique opportunity right now to be the leaders and experts that hold the know how in accelerating significant advancements across complex development and production processes.
Enhanced Viral Vector Yield & Quality ~ Market Analyst @ Virica | Curated Cell & Gene Therapy Insights| Business Development | Biotechnology|
More than 400 CDMO’s in the small molecule, biologics, cell and gene therapy space! And that’s growing as demand for cell and gene therapy continues to rise! An overcrowded space means CDMOs must differentiate. Especially with several new entrants, including Lifeera, Kincell, and NewBiologix. Source: BioKnow #biomanufacturing #innovation #CDMOs
Enhanced Viral Vector Yield & Quality ~ Market Analyst @ Virica | Curated Cell & Gene Therapy Insights| Business Development | Biotechnology|
2moI couldn't agree with you more! Well said Renee!